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Background: Recent studies provide evidence of improved clinical benefits associated with cardiac resynchronization
therapy (CRT) optimization. Our analysis explores the cost-effectiveness of systematically optimized (SO, 3 times a year)
vs. non-systematically optimized (NSO, less than 3 times a year) CRT, whatever the echo optimization method used
(manual or SonR® automatic).
A longitudinal cohort model was developed to predict clinical and economic outcomes for SO vs. NSO strategies over
5 years. The analysis was performed from the payer perspective. Data from CLEAR study post-hoc analysis was used with
199 pts with CRT pacemaker (CRT-P). The main economic outcome measure was incremental cost-effectiveness (ICER)
expressed as cost per Quality Adjusted Life Years (QALY) gained. To assess the impact of data uncertainty, a sensitivity
analysis was performed. The model also predicts outcomes for the two optimization strategies for CRT-D therapy vs.
optimal medical treatment (OPT).
Results: At 1 year, ICERs for SO CRT vs. NSO CRT-P range between € 22,226 (Spain) and € 26,977 (Italy). Therefore,
on the basis of a Willingness-To-Pay of €30,000 per QALY, the SO method develops into a cost effective strategy
from 1 year, onwards. These favorable outcomes are supported by the sensitivity analysis. Systematic optimization
of CRT-D might also improve the cost-effectiveness of this device therapy by 27 % to 30 % dependent on the
country analyzed, at 5 years.
Conclusions: Our economic evaluation shows promising health economic benefits associated with SO CRT.
These preliminary findings need further confirmation.
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Heart failure (HF) is a growing worldwide public health
issue and constitutes enormous medical, social and eco-
nomic problems. In Europe, 1-2 % of the general popula-
tion is affected by HF with a rapid increase in prevalence
for the older age groups [1, 2]. Around 3.5 million people
are newly diagnosed with HF every year [3]. Morbidity and
mortality caused by this chronic and progressive disease is* Correspondence: kurt.banz@outcomes.ch
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provided the original work is properly creditedsubstantial with observed death rates after one year of
diagnosis as high as 40 % without adequate therapy [4–6].
Due to its significant frequency coupled with the high mor-
bidity and mortality, medical resource utilization devoted
to the care of patients with HF is considerable, resulting in
a high financial burden to healthcare payers. For numerous
developed countries the management of HF has been
shown to account for at least 1-2 % of total health care ex-
penditures [7].
For the treatment of patients with advanced HF and
evidence of intraventricular conduction delay who aree distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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resynchronization therapy (CRT) is the established standard
treatment. The clinical benefits conferred by CRT in se-
lected patient populations with advanced HF and cardiac
dyssynchrony have been unequivocally demonstrated in nu-
merous controlled trials [8]. Benefits include improve-
ments in the clinical status and functional capacity, cardiac
remodeling, reduction in the frequency of hospitalizations
from HF, prolongation of survival, and an increase in the
quality of life. However, about 30-40 % of recipients of
CRT may not improve in their clinical status based on
current selection criteria [8]. This significant non-response
rate can be ascribed to a variety of reasons including sub-
optimal patient selection, inappropriate lead positioning, or
suboptimal CRT programming (device optimization) [9]. It
is now recognized that optimal follow-up of patients with
CRT is crucial for ensuring that patients will derive
maximum benefit from this therapy [10]. Continuous
optimization of both atrioventricular delay (AVD) and
interventricular delay (VVD) has been advocated as
technique to improve responder rates [11, 12].
The meta-analysis done by Auger et al. [13] clearly
emphasizes the ambiguity of the conclusions of previous
studies related to AV-VV optimization. Among the method
described by the author, echo-optimization method (either
done manually or automatically) shows much more prom-
ising outcomes as compared with other methods. One of
the difficulties related to echo-optimization is ability to
replicate consistently echoes. Previous studies have illus-
trated that resource constrains (availability of echo staff
and time) impede doctors from doing AV-VV optimization
even if guidelines indicate that optimization is an alterna-
tive for non-responders [14].
In addition, echocardiography is often inadequately
reimbursed. Consequently, CRT is usually not system-
atically optimized in routine clinical practice [15, 16].
This has been demonstrated by a recent survey which
discovered that echo-optimization is performed infre-
quently whether at the time of system implant, or during
follow-up [15]. In an effort to overcome these challenges,
automated methods adapting CRT delivery according to
patients’ changing needs are being developed, allowing a
more efficient approach to CRT optimization. However,
earlier non-echo CRT optimization algorithms have pro-
duced inconclusive results in terms of clinical benefits, call-
ing for new methods [15]. The CLEAR (Clinical Evaluation
on Advanced Resynchronization, Clinicaltrial.gov registra-
tion number: NCT00658203) pilot study is the first trial
showing a trend towards better outcomes associated with
automated AVD and VVD optimization employing a
hemodynamic sensor that records the peak endocardial ac-
celeration (SonR) signal [12]. The SonR signal is correlated
to hemodynamic measures [17] and allows automatic echo
optimization according to a method similar to the RITTERformula. In a recent post-hoc analysis of patients having
completed the CLEAR pilot study, clinical benefits con-
ferred by systematic CRT optimization in comparison to
non-systematic optimization over a follow-up period of one
year have been reported [18].
Due to the significant up-front cost, there has been great
interest in evaluations of whether CRT therapy, potentially
combined with a defibrillator (CRT-D), is cost-effective
when compared to optimal pharmacological treatment
alone [19]. Yet, none of these economic studies had specif-
ically addressed the consequences associated with differ-
ent follow-up CRT optimization strategies. Since first
study data showing the beneficial impact of optimization
on clinical outcomes are emerging, our exploratory analysis
therefore sought to assess the economic value of CRT im-
plantation with systematic optimization (SO, 3 times a year)
in comparison to standard (non-systematic, NSO) CRT
optimization (less than 3 times a year), in five European
countries (Germany, France, Italy, Spain, and the UK).
Methods
Longitudinal deterministic model
A longitudinal deterministic cohort model was devel-
oped to evaluate the clinical and economic outcomes
for a group of CRT recipients with systematic CRT
optimization subsequently to device implantation vs. a
group with standard (NSO) optimization, whatever the
method used (echo-based or using the SonR system). A
healthcare (payer) perspective was considered for the eco-
nomic analysis. The model allows predicting outcomes
(death, HF hospitalization, NYHA class distribution) up to
5 years with distinctive analysis time points at 1, 2, 3 and
4 years. The model predicts cumulative total costs and
health outcomes, i.e., quality adjusted life years (QALYs)
accrued over time, and the incremental cost-effectiveness
ratio (ICER) of SO vs. NSO CRT-P. Sensitivity analyses
were performed to assess the impact of variations in as-
sumptions of key model parameters on the economic out-
come. Furthermore, a hypothetical scenario analysis was
executed to estimate the potential cost-effectiveness of SO
and NSO CRT-D recipients in comparison to patients
treated with optimal pharmacological therapy (OPT) alone.
Data sources
For our analysis, data from a post-hoc analysis of the
CLEAR study was used, it included all patients (n = 199)
who had a successful CRT pacemaker implantation and
who completed the 1-year follow-up [18]. The group of
patients with SO comprised 66 individuals who were sys-
tematically optimized at all 3 pre-specified visits (post-
hospitalization, 3 and 6 months), whereas the NSO group
included 133 patients who were optimized less than 3
times a year, regardless of the echo optimization method
used (either manual- or by the SonR echo based system).
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tributions of NYHA functional classes were retrieved from
the CLEAR post-hoc analysis, for the 2 groups, at each
time point up to one year (Table 1).
Base case
Individual CRT optimization regimens can be simulated.
As types of optimization procedures performed can vary
and related time needs and tariffs can differ, the model
permits a choice between a routine consultation, a consult-
ation including echo control, or a consultation with echo
optimization. Model assumptions on the CRT optimization
schedules for the 2 groups are in accordance with the
optimization procedures reported in the CLEAR post-hoc
study (Additional file 1: Table A).
As the CLEAR study provides data for a follow-up
period of one year only [18], assumptions were employed
to inform the model for the time periods from 2 years and
beyond. Considering the exploratory purpose of this ana-
lysis, conservative assumptions were selected as comparedTable 1 Base case clinical model input data assumptions
Model variable
Month 1 Month 3 Month 6 Yea
All-cause mortalitya
Systematic CRT optimization 0.0 % 0.0 % 3.0 % 6.8
Standard CRT optimization 1.5 % 3.0 % 6.8 % 14.
HF hospitalizationb
Systematic CRT optimization 0.0 % 3.0 % 7.6 % 12.
Standard CRT optimization 3.8 % 8.3 % 13.5 % 23.
Mean NYHA class Baseline Month 3 Month 6 Yea
Systematic CRT optimization
NYHA I 0 % 16.9 % 26.6 % 22.
NYHA II 10.9 % 75.4 % 65.6 % 63.
NYHA III 87.5 % 7.7 % 7.8 % 14.
NYHA IV 1.6 % 0 % 0 % 0 %
Standard CRT optimization
NYHA I 0 % 8.5 % 18.7 % 13.
NYHA II 6.9 % 62.7 % 58.0 % 56.
NYHA III 86.1 % 28.0 % 20.5 % 27.
NYHA IV 6.9 % 0.8 % 2.7 % 1.8
Health utilities by NYHA class
NYHA class I 0.815
NYHA class II 0.720
NYHA class III 0.590
NYHA class IV 0.508
Death 0
aIn accordance with the conservative approach adopted for the present analysis, th
optimization group was assumed to be identical to that applied to the standard CR
assumed to cease after one year of follow-up
bValues are presented as cumulative probabilitywith actual rates. In order to draw reasonable assumptions
beyond 1 year, mortality and HF hospitalization rates at
1 year in the SO group were adjusted as an average be-
tween the actual rate and the upper confidence interval
limit (CI) from the CLEAR post-hoc analysis (Fig. 1). Be-
yond 1 year, the incremental increase in mortality was
assumed to be identical to that applied to the NSO group,
which has been derived from CARE-HF long-term CRT
outcome study published by Cleland and co-workers [20].
As the CLEAR study population is older than the CARE-
HF population, assumptions relative to mortality for the
NSO arm refer to long-term CARE-HF clinical data for
patients above 66 years [20]. This is considered a conser-
vative assumption, implying that the demonstrated sur-
vival benefits related to SO which has been observed
during the first year will not continue thereafter (Table 1).
With regard to assumptions on the probability of HF
hospitalizations after one year for patients with NSO, a
linear increase was assumed based on the incremental
rate of hospitalization between 6 and 12 monthsSource
r1 Year 2 Year 3 Year 4 Year 5
% 17.8 %a 25.8 % 33.8 % 40.8 % [18, 20], assumption
3 % 25.3 % 33.3 % 41.3 % 48.3 % [18, 20]
2 % 22.5 % 32.7 % 43.0 % 52.4 % [18], assumption
3 % 42.9 % 62.5 % 82.1 % 100.0 % [18], assumption
r 1 Year 2 Year 3 Year 4 Year 5
[18], assumption
2 % 22.2 % 22.2 % 22.2 % 22.2 %
5 % 63.5 % 63.5 % 63.5 % 63.5 %
3 % 14.3 % 14.3 % 14.3 % 14.3 %
0 % 0 % 0 % 0 %
[18], assumption
8 % 13.8 % 13.8 % 13.8 % 13.8 %
9 % 56.9 % 56.9 % 56.9 % 56.9 %
5 % 27.5 % 27.5 % 27.5 % 27.5 %






e incremental increase in mortality after 1 year for the systematic CRT
T optimization group, i.e. benefits of CRT optimization on mortality were
Fig. 1 Death rate with the value of the average between the actual rate and the upper confidence interval limit in the CLEAR study and CARE-HF
study (patients >66 year-old), at 1 year
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From an economic point of view, hospital admissions
caused by acute episodes of HF are of particular import-
ance for the analysis, as these events are frequent and
costly. This is also apparent from the CLEAR study,
particularly as concerns the NSO group, which shows a
substantial percentage of patients requiring hospitalization
for acute HF symptoms in the first year after implantation.
In contrast, SO leads to a significant decrease in the fre-
quency of rehospitalizations. One year post-hoc study data
further indicated that for each hospitalized patient, the
mean number of admissions was 1.4 in both groups, and
was thus also factored into our economic model. In order
to validate this assumption, information on the probability
of HF hospitalization presented by Anand and co-workers
was reviewed [21]. A comparison of the frequency of HF
hospital admissions (considering recurrent admissions)
within the first year after CRT implantation showed an ex-
cellent fit between the CLEAR study and this reference.
This analysis is in line with a recent publication from
Maneikiene and co-authors relative to the outcome of car-
diac resynchronization therapy in older patients [22]. In
addition, the increase in the cumulative probability of HF
hospitalization with ongoing follow-up time (up to around
2.5 years) as observed by Anand showed a strong ten-
dency for a linear correlation, which substantiates the
longer-term assumptions applied to our model.
In terms of the frequency of HF hospitalizations after
one year for the systematic optimization group, the same
relative increase in the probability of HF events as as-
sumed for the SO group was applied. This approach
accounts for expected long-term benefits of SO on re-
hospitalizations (Table 1).Regarding the NYHA class, the distribution observed at
the one year follow-up of the CLEAR post-hoc study was
assumed to remain unchanged up to 5 years (Table 1).
Quality-adjusted life-years (QALYs)
Patients’ status in the SO group was associated with more
frequent transitions towards lower NYHA functional
classes than observed for patients with non-systematic
optimization according to the CLEAR post-hoc analysis.
This beneficial effect led to a decrease in persisting symp-
toms of cardiac insufficiency and consequently improves
the quality of life (QoL) of HF patients. The majority of
previous economic model analyses evaluating the effects
of CRT have also considered shifts in QoL, typically by
accounting for changes in distributions of subjects in
the compared groups across the four NYHA classes
over time and assigning a utility weight to each NYHA
class in order to compute QALYs [19, 23]. Therefore,
the model calculated the cumulative number of QALYs
in each group, by assigning health utilities to each
NYHA functional class patients’ distribution and death
rate (Table 1).
Economic data
Country-specific tariffs were allocated to medical resource
use items, including CRT implantation, hospital readmis-
sions due to HF episodes or complications, and follow-up
physician visits including diagnostic examinations associ-
ated with CRT (Table 2). Pharmacological treatment costs
were based on prices from national drug compendiums.
All unit cost data used to inform the model were adjusted
to fiscal year 2012. Half-cycle correction methods were
applied to the computation of both costs and effectiveness
Table 2 Base case economic model input data assumptions
Model variable Germany France Spain Italy UK
Tariff for CRT-P implantationa € 11.924 € 9.412 € 10,791 € 8,921 £ 8,281
Actual cost of CRT € 12,326 € 9,280 € 11,121 € 8,455 £ 6,474
Cost of CRT procedure
CRT-P device incl. leads € 5,569 € 5,816 € 5,428 € 3,950 £ 3,411
Other costsb € 3,169 € 1,654 NA € 718 £ 1,555
Premium for sensor leadc € 2,000 € 2,000 € 2,000 € 2,000 £ 1,665
Unit cost follow-up HF hospitalizationd € 2,328 € 3,577 € 3,364 € 3,052 £ 3,411
Average monthly cost of optimal drug therapye € 59 € 18 € 18 € 18 £ 22
Tariff for CRT optimization services
Routine cardiology consultation € 28 € 61 € 45 € 21 £ 62
Consultation with echocardiographic control € 28 € 96 € 79 € 52 £ 86
Device optimization by echocardiography € 73 € 96 € 147 € 52 £ 120
Actual costs for CRT optimization servicesf
Routine cardiology consultation € 24 € 28 € 19 € 17 £ 17
Consultation with echocardiographic control € 62 € 70 € 48 € 36 £ 43
Device optimization by echocardiography € 147 € 169 € 115 € 87 £ 101
Discount rate
Costs 3.0 % 3.0 % 3.0 % 3.0 % 3.5 %
Benefits 3.0 % 3.0 % 3.0 % 3.0 % 3.5 %
aWeighted tariff taking into account the relative frequency of implantations by DRG severity category and corresponding tariffs (applies if more than one DRG for
CRT is reported in the DRG catalogue)
bE.g. cost for personnel involved in CRT implantation, diagnostic examinations, disposables/consumables, medication, overhead costs
cAssumption as there is currently no information on the extra cost for the sensor lead available; this expense was applied to the systematic optimization group
only and also taken into account (conservative approach) for the analysis performed from the perspective of the healthcare payer although the current DRG tariff
for CRT would currently include this expense
dPer stay
eFor Germany based on reference [26]; for the UK based on reference [27]; for remaining countries based on own assumptions
fComputed from the estimated duration of optimization service and hourly cost of personnel involved in the optimization procedures (CRT and/or echo specialist)
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according to recommended rates as specified in national
health economic guidelines. Table 2 summarizes the eco-
nomic input data for the different economic model vari-
ables and for the base case analysis involving patients with
CRT-P implantation. For the purpose of our analysis, an
extra expense of €2,000 was assumed for additional
optimization for SO (echo- or SonR-based optimization)
vs. NSO. This is consistent with previous investigations
identifying lack of resource as one of the key difficulties in
conducting more systematically echo optimization [16]. In
terms of the threshold determining cost-effectiveness, a
commonly used willingness-to-pay (WTP) threshold of £
25,000 (€ 30,000) as recommended by the National Insti-
tute of Health and Care Excellence (NICE) was employed.
Sensitivity analyses
To assess the impact of data uncertainty on the eco-
nomic outcomes of the base case analysis, univariate and
probabilistic sensitivity analyses were performed, consid-
ering the model parameters and assumptions summa-
rized in the Additional file 1: Table B. Such a sensitivityanalysis is important to assess the robustness of results
and conclusions derived from the economic analysis.
Exploratory CRT-D analysis
An additional scenario analysis was performed to assess
the cost-effectiveness of both SO and NSO CRT-D vs.
optimal pharmacological treatment alone (OPT). For
this assessment, the incidence of follow-up events ob-
served in the CLEAR post-hoc study (in which a CRT
device without a defibrillator was implanted) were recal-
culated on the basis of exclusion of those patients from
the re-analysis who have died for reasons of sudden
cardiac death. This event has been witnessed in 1 patient
randomized to the systematic optimization group and 3
patients randomized to the NSO group. This approach
suggests that sudden cardiac deaths would have been
prevented if CRT-D instead of CRT-P devices would
have been used. We assumed no additional benefit at-
tributable to ICD as the frequency of other follow-up
events has been reported to be similar for CRT-P and
CRT-D patients. Economic input data were adjusted
where appropriate to be consistent with the CRT-D
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was executed to estimate the potential cost-effectiveness
of systematic and standard optimization in CRT-D re-
cipients in comparison to patients treated with OPT.
To inform the OPT arm of our model, results from
the CARE-HF study (patients >66 years-old) were used
as assumptions for the cumulative percentage of pa-
tients experiencing death and hospital admission due
to HF over the first two years [20]. For subsequent
analysis time points, annual increases in the percent-
age of these two main events as observed in the
CARF-HF study between one and two years were ap-
plied [20]. NYHA distribution for OPT patients was
assumed to be identical to that applied to CRT-D
patients at baseline and was assumed to remain un-
changed over the 5 year follow-up and the average
number of hospitalizations per hospitalized patient
was adjusted to 2.3 admissions (1.4 for CRT recipi-
ents) based on evidence from randomized trials.Table 3 Base case results by treatment group (systematic vs. standa
payer (values represent discounted average per-patient outcomes)
Country 1 year
Germany
Total cost – systematic optimization group € 15,120
Total cost – standard optimization group € 13,532
Increment (systematic vs. standard) € 1,588
Total QALYs – systematic optimization group 0.71
Total QALYs – standard optimization group 0.64
Increment (systematic vs. standard) 0.07
ICERa € 26,973
Franceb
Incremental total cost (systematic vs. standard) € 1,357
Incremental total QALYs (systematic vs. standard) 0.07
ICER € 23,053
Spainb
Incremental total cost (systematic vs. standard) € 1,309
Incremental total QALYs (systematic vs. standard) 0.07
ICER € 22,226
Italyb
Incremental total cost (systematic vs. standard) € 1,588
Incremental total QALYs (systematic vs. standard) 0.07
ICER € 26,977
UKb
Incremental total cost (systematic vs. standard) £ 1,224
Incremental total QALYs (systematic vs. standard) 0.07
ICER £ 20,787
aThe ICER is expressed as cost per QALY gained
bOnly incremental outcomes and ICERs are tabulated for these countriesResults
Table 3 summarizes discounted results of the exploratory
base case analysis performed from the perspective of the
healthcare payer by analyzed time point and by country
for patients with CRT implantation. According to these
findings, systematic CRT-P device optimization leads to a
survival benefit and improved quality-of-life as compared
to standard (non-systematic) device optimization. By
the end of the first year, systematic device optimization
results in a gain of 0.07 QALYs per patient, whereas
this benefit increased up to 0.33 QALYs by year 5. With
regard to total costs, these remain higher during the
early follow-up period for SO, mainly caused by the
consideration of a hypothetical extra cost for additional
procedure (either a systematic echo procedure or im-
plantation of the SonR sensor) (€ 2,000 or £ 1,665).
With ongoing follow-up time, however, these additional
costs can partially be offset in the evaluated countries due
to savings attributable to prevented HF hospitalizations.rd CRT-P optimization) from the perspective of the healthcare
2 years 3 years 4 years 5 years
€ 16,143 € 17,063 € 17,897 € 18,625
€ 14,769 € 15,896 € 16,930 € 17,832
€ 1,375 € 1,168 € 967 € 793
1.32 1.85 2.32 2.72
1.19 1.65 2.05 2.39
0.13 0.21 0.27 0.33
€ 10,224 € 5,690 € 3,556 € 2 371
€ 971 € 596 € 232 € −88
0.13 0.21 0.27 0.33
€ 7,222 € 2,904 € 853 Dominant
€ 943 € 587 € 242 € −61
0.13 0.21 0.27 0.33
€ 7,010 € 2,862 € 892 Dominant
€ 1,333 € 1,076 € 820 € 594
0.13 0.21 0.27 0.33
€ 9,912 € 5,244 € 3,017 € 1 775
£ 993 £ 770 £ 554 £ 367
0.13 0.21 0.27 0.33
£ 7,405 £ 3,771 £ 2,055 £ 1,109
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returns favorable ICERs (cost per QALY) already at the
one year follow-up for all five countries, ranging between
€ 22,226 (Spain) and € 26,977 (Italy).
By applying the low and high estimates for main model
variables (Additional file 1: Table B, example for Germany),
the accomplished one-way sensitivity analysis indicated the
incremental expense for the automatic sensor lead taken
into account for the SO group to be the parameter with the
most distinct impact on the incremental cost-effectiveness
ratio (ICER) at the 5-year analysis time horizon as illus-
trated in Fig. 2. Further variables with sizable effects on the
ICER include the risk reduction for all-cause mortality
(in the worst case, a zero risk reduction on mortality was
considered for systematic CRT optimization) and for HF
hospitalization ascribed to the SO group. In contrast, varia-
tions in the discount rates for costs and benefits were found
to affect the ICERs only marginally. The probabilistic sensi-
tivity analysis performed in addition substantiated the valid-
ity of the favorable base case results. For this second
sensitivity analysis, 1,000 simulations were performed in
which values of all selected key model variables were chan-
ged simultaneously (Additional file 1: Table B). The findings
resulting from the probabilistic sensitivity analysis con-
firmed the robustness of the base case results as shown in
Figs. 3 and 4. Of the 1,000 simulations performed, 47.6 %
of ICERs computed for the 1 year follow-up time point
were found to be lower than the specified willingness-to-
pay threshold (WTP) of €30,000. Already after 2 years, thisFig. 2 One-way sensitivity analysis illustrating the impact of main model va
follow-up time horizon (healthcare payer perspective, Germany)percentage increases to 99.9 % and after 5 years all com-
puted ICERs were below the specified WTP.
Exploratory CRT-D analysis
Extrapolating the clinical effects of systematic CRT-P
optimization to a hypothetical CRT-D setting, cost-ef-
fectiveness results that were almost equivalent to those
produced for CRT-P patients were predicted by our
model (comparison of systematic vs. standard CRT-D
optimization). Systematic optimization might contribute
to improve the CRT-D cost-effectiveness (ratio of sys-
tematic CRT-D vs. OPT and standard CRT-D vs. OPT)
by 27 % to 30 % depending on the country analyzed
(Table 4).
Discussion
Despite the evidence-based clinical benefit of CRT, about
one third of CRT patients are commonly considered non-
responders. One variable that may influence therapy
response is the quality of follow-up device optimization
[11]. However, the debate on the need for routine, system-
atic AVD and VVD optimization in all patients undergo-
ing CRT remains controversial [13, 24]. Furthermore, first
guidelines on the optimization of CRT in routine clinical
practice have been published only very recently [24],
which may be another reason for the suboptimal follow-
up programming of CRT devices reported by a recent
international survey [16]. Main causes for suboptimal
optimization were time constraints of medical specialistsriables on the incremental cost-effectiveness ratio for the 5-year
Fig. 3 Scatterplot illustrating incremental costs versus incremental benefits (QALYs) for a 1-year, 2-year, and 5-year follow-up time horizon (n = 1,000
simulations, healthcare payer perspective, Germany)
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situation calls for less time-consuming optimization
methods. Therefore, CRT systems which facilitate follow-
up device optimization are being developed and clinically
evaluated [13]. For the first time to our knowledge, the
post-hoc analysis of the CLEAR pilot study provided pre-
liminary evidence of superior clinical outcomes in terms
of reduced mortality and less HF hospitalizations for
patients with SO compared to standard practice (NSO)
device optimization over a follow-up of one year [18].
The economic consequences pertaining to different
follow-up CRT optimization schedules have not been in-
vestigated to date except for a budget impact analysisFig. 4 Cost-effectiveness acceptability curve with results produced for a 1-y
healthcare payer perspective, Germany)from the perspective of the United States Medicare pay-
ment setting which predict savings to occur with auto-
matic CRT devices [13]. We therefore sought to conduct
an exploratory cost-effectiveness analysis based on out-
come data from the CLEAR post-hoc analysis, comple-
mented by assumptions for the analysis time period
between one and 5 years. Whereas identical clinical as-
sumptions were used as model input data for all five
analyzed countries, economic input data was country-
specific due to differences in medical tariffs and direct
medical resource utilization. We applied a hypothetical
premium of € 2,000 (£ 1,665) to patients allocated to
additional optimization procedures (related to echo-basedear, 2-year, and 5-year follow-up time horizon (n = 1,000 simulations,
Table 4 Cost-effectiveness of systematic CRT-D optimization
versus optimal pharmacological therapy (OPT) from the
perspective of the healthcare payer








Germany € 16,359 € 22,327 -27 %
France € 16,052 € 23,019 -30 %
Spain € 24,440 € 34,936 -30 %
Italy € 15,077 € 20,738 -27 %
UK £ 14,950 £ 20,861 -28 %
aICERs are expressed as cost per QALY gained
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ducting the economic model analysis from the perspec-
tive of the healthcare payer, favorable cost-effectiveness
results were obtained for the CRT group with SO vs.
NSO, in all five countries. ICERs at the 1 year follow-
up were found to range from € 22,226 (Spain) to € 26,977
(Italy) per QALY gained. This implies that already after
one year, ICERs are well below the commonly accepted
willingness-to-pay threshold of € 30,000 (£ 25,000) deter-
mining cost-effectiveness. Because of savings in the sys-
tematically optimized group attributable to avoided HF
hospitalizations over one year, the assumed premium for
systematic optimization can be partially offset in subse-
quent years. Cost savings accrue during subsequent
follow-up time periods so that this method becomes even
more cost effective after 1 year in all countries. These fa-
vorable preliminary economic outcomes were confirmed
by results from the sensitivity analysis. The savings in HF
hospitalization costs predicted by the model are consistent
with the results from the abstract published by Tarab
and co-workers for adaptive CRT in the US [25]. The
average hospitalization reduction per year (normalized
by HF hospitalization cost to neutralize differences be-
tween countries) is close to 12 % in our model as com-
pared with 10 % for the Adaptive CRT device (Medtronic,
Minneapolis, MN, USA).
According to these preliminary findings, systematic CRT
optimization represents integral part of the long-term
management of CRT patients. However, CRT optimization
with traditional echocardiography methods is time con-
suming and inadequately reimbursed in most countries,
resulting in a suboptimal optimization management of
CRT recipients. Devices with frequent and systematic re-
programming features might therefore be excellent tools
which can aid to alleviate the time burden for follow-up
device optimization performed by medical specialists treat-
ing CRT patients.
Our exploratory economic model analysis has a
number of limitations. Due to a shortage of long-termclinical study data, we had to use assumptions on the
probability of HF hospitalizations and survival in both
groups for the follow-up time periods exceeding one
year. We also restricted the time horizon of the analysis
to five years although a sizable proportion of patients with
systematic CRT optimization are predicted to be alive
after this time and who could further benefit from the sus-
tained effects delivered by systematic optimization. Add-
itionally, health state utilities directly derived from the
CLEAR post-hoc study were not available. Therefore, our
assumptions require confirmation by further randomized
long-term studies.
Based on the promising cost-effectiveness results from
our exploratory economic analysis, systematic CRT optimi
zation should be given more attention in the follow-up rou-
tine management of device recipients. However, time
restrictions for CRT-specialists will most likely remain to
exist for the present and will challenge a rapid adoption of
this apparently beneficial method. Programming of system-
atic and frequent CRT optimization through implanted de-
vices might be the future to at least partially resolve these
issues.Conclusions
A longitudinal economic cohort model was developed to
assess the cost-effectiveness of systematic CRT optimization
(3 times a year) vs. non-systematic CRT optimization (less
than 3 times a year), whatever the method used (manual
echo or device-based using SonR®) in five European coun-
tries. The model predicted an incremental cost-effectiveness
ratio (ICER) ranging between € 22,226 for Spain and
€ 26,977 for Italy at the 1-year follow-up. Employing a
willingness-to-pay threshold of € 30,000 per QALY gained,
the SO method developed into a cost-effective strategy
from one year onwards. An exploratory analysis on
CRT-D optimization showed that SO could improve
cost-effectiveness by 27 % to 30 % (SO CRT-D vs. opti-
mal pharmacological treatment alone and standard
CRT-D vs. optimal treatment, respectively) at 5 years of
follow-up, depending on the country analyzed.Additional file
Additional file 1: Table A. Model assumptions for CRT optimization
schedules. Table B. Assumptions for sensitivity analysis (example for
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